Browsing Over 990 Presentations
Sort By
Q&A and closing remarks (ID 1800)
Recent advances in metastatic prostate cancer management (ID 1881)
PARPi maintenance: A new paradigm in the management of frontline ovarian cancer (ID 1784)
Welcome, introductions and objectives of the session (ID 1801)
Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion (ID 1882)
What’s new in metastatic pancreatic cancer management? (ID 1785)
The landscape and role of IO-Chemo combination in NSCLC treatment (ID 1802)
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
ESMO Colloquium
Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC
Lecture Time
12:50 PM - 01:15 PM
Session Name
Speakers
- Marina C. Garassino
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
- Marina C. Garassino
Q&A (ID 1787)
Is immuno-oncology going to replace chemotherapy in advanced HNSCC? (ID 1803)
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
ESMO Colloquium
EGFR mutant mNSCLC: Single agent or in combination?
Lecture Time
01:15 PM - 01:40 PM
Session Name
Speakers
- Fabrice Barlesi
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
- Fabrice Barlesi